OTCPK:SMTI

Stock Analysis Report

Executive Summary

Sanara MedTech Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Sanara MedTech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.0%

SMTI

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

88.5%

SMTI

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: SMTI exceeded the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: SMTI exceeded the US Market which returned 7.3% over the past year.


Shareholder returns

SMTIIndustryMarket
7 Day5.0%2.0%1.8%
30 Day23.5%-1.8%-0.7%
90 Day45.8%-0.5%0.06%
1 Year88.5%88.5%14.2%13.3%9.7%7.3%
3 Year110.4%110.4%70.5%65.3%46.3%36.9%
5 Year32.9%32.9%127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Sanara MedTech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sanara MedTech undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Sanara MedTech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sanara MedTech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of SMTI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Sanara MedTech regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Sanara MedTech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sanara MedTech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of SMTI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Sanara MedTech's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Sanara MedTech performed over the past 5 years?

50.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SMTI is unprofitable, but has reduced losses over the past 5 years at a rate of 50.3% per year.

Accelerating Growth: Unable to compare SMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SMTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: SMTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: SMTI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SMTI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sanara MedTech's financial position?


Financial Position Analysis

Short Term Liabilities: SMTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: SMTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: SMTI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: SMTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: SMTI has a low level of unsold assets or inventory.

Debt Coverage by Assets: SMTI has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if SMTI has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SMTI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Sanara MedTech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SMTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SMTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sanara MedTech's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Mike Carmena (63yo)

1.7yrs

Tenure

US$207,107

Compensation

Mr. J. Michael Carmena, also known as Mike, has been Vice Chairman of Sanara MedTech Inc. since May 2019. Mr. Carmena has been Chief Executive Officer and Director of Sanara MedTech Inc. (f/k/a WNDM Medic ...


CEO Compensation Analysis

Compensation vs. Market: Mike has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.5yrs

Average Tenure

63yo

Average Age

Experienced Management: SMTI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

0.4yrs

Average Tenure

63yo

Average Age

Experienced Board: SMTI's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ron Nixon (63yo)

    Executive Chairman

    • Tenure: 0yrs
  • Cathy Bradshaw (66yo)

    President of Wound Care Innovations LLC

    • Tenure: 11.3yrs
    • Compensation: US$145.00k
  • Jane Fore

    Chief Medical Officer

    • Tenure: 5.6yrs
  • Mike Carmena (63yo)

    Vice Chairman & CEO

    • Tenure: 1.7yrs
    • Compensation: US$207.11k
  • Zach Fleming

    President of Surgical Division

    • Tenure: 0.4yrs
  • Mike McNeil (53yo)

    Chief Financial Officer

    • Tenure: 1.5yrs
    • Compensation: US$184.76k
  • Shawn Bowman

    President of Wound Care Division

    • Tenure: 0.4yrs
  • Callon Nichols

    Director of Investor Relations

    • Tenure: 0.2yrs
  • Tricia Matteson

    Senior Director of Marketing

    • Tenure: 0yrs
  • Carla Day

    Director of Customer & Sales Services

    • Tenure: 0yrs

Board Members

  • Ron Nixon (63yo)

    Executive Chairman

    • Tenure: 0yrs
  • Denny Howell (79yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$10.50k
  • Jim Stuckert (81yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$10.50k
  • Ann Salamone

    Director

    • Tenure: 0.2yrs
  • Ken Thorpe (62yo)

    Director

    • Tenure: 0.2yrs
  • Mike Carmena (63yo)

    Vice Chairman & CEO

    • Tenure: 1.7yrs
    • Compensation: US$207.11k

Company Information

Sanara MedTech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sanara MedTech Inc.
  • Ticker: SMTI
  • Exchange: OTCPK
  • Founded: 1982
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$24.845m
  • Shares outstanding: 2.37m
  • Website: https://www.wndm.com

Number of Employees


Location

  • Sanara MedTech Inc.
  • 1200 Summit Avenue
  • Suite 414
  • Fort Worth
  • Texas
  • 76102
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SMTIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 1991

Biography

Sanara MedTech Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. It offers HemaQuell, a resorbable bone hemostat for bone healing; a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:10
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.